0001104659-24-119843.txt : 20241115 0001104659-24-119843.hdr.sgml : 20241115 20241115213013 ACCESSION NUMBER: 0001104659-24-119843 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241114 FILED AS OF DATE: 20241115 DATE AS OF CHANGE: 20241115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mastrocola Lauren CENTRAL INDEX KEY: 0001827639 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39620 FILM NUMBER: 241469595 MAIL ADDRESS: STREET 1: C/O PRAXIS PRECISION MEDICINES, INC. STREET 2: ONE BROADWAY, 16TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Praxis Precision Medicines, Inc. CENTRAL INDEX KEY: 0001689548 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-300-8460 MAIL ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 tm2428636-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-11-14 0 0001689548 Praxis Precision Medicines, Inc. PRAX 0001827639 Mastrocola Lauren C/O PRAXIS PRECISION MEDICINES, INC. 99 HIGH STREET, 30TH FLOOR BOSTON MA 02110 0 1 0 0 Principal Accounting Officer 0 Common Stock 2024-11-14 4 M 0 4374 56.94 A 10801 D Common Stock 2024-11-14 4 S 0 5188.344 81.783 D 5612.656 D Stock Option (Right to Buy) 56.94 2024-11-14 4 M 0 4374 0 D 2034-07-29 Common Stock 4374 16626 D The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $81.23 to $81.797. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the reporting person's continued service through each vesting date. The transactions reported in this Form 4 were effected for estate planning purposes. /s/ Alex Nemiroff, as Attorney-in-Fact 2024-11-15